In conclusion, treatment with cotadutide in patients with T2DM and overweight or obesity led to significant and physiologically meaningful reductions in liver glycogen and fat compared with placebo and liraglutide, supporting engagement with the glucagon receptor in the human liver to promote offloading of excess energy substrates. Here, GCGR is linked to type 2 diabetes mellitus.